Discordances among different tools used to estimate cardiovascular risk in postmenopausal women

Canadian Journal of Cardiology

Volumn 25, Issue 12, 2009, Pages

  Pelletier, Pascal ^a   Lapointe, Annie ^b   Laflamme, Nathalie ^a   Piché, Marie Eve ^b   Weisnagel, Stanley John ^a   Nadeau, André ^c   Lemieux, Simone ^b   Bergeron, Jean ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c NONE

Author keywords

CVD risk assessment; Framingham risk score; hs CRP; Metabolic syndrome; Women's health

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FRAMINGHAM RISK SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; POSTMENOPAUSE; SCORING SYSTEM;

EID: 73649129240     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70535-5     Document Type: Article

References (32)

1. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-9.
2. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006;119:812-9.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
4. Piche ME, Lemieux S, Weisnagel SJ, et al. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 2005;96:92-7.
5. Couillard C, Despres JP, Lamarche B, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: Evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001;21:1226-32.
6. McPherson R, Frohlich J, Fodor G, et al. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27.
7. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-S201.
8. Thorand B, Baumert J, Doring A, et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006;184:216-24.
9. Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105:564-9.
10. Festa A, D'Agostino R Jr, Williams K, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001;25:1407-15.
11. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
12. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999;22:1971-7.
13. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005;69:29-35.
14. Rexrode KM, Pradhan A, Manson JE, et al. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003;13:674-82.
15. Piche ME, Weisnagel SJ, Corneau L, et al. Contribution of abdominal visceral obesity and insulin resistance to the cardiovascular risk profile of postmenopausal women. Diabetes 2005;54:770-7.
16. Lear SA, Chen MM, Birmingham CL, et al. The relationship between simple anthropometric indices and C-reactive protein: Ethnic and gender differences. Metabolism 2003;52:1542-6.
17. Lakoski SG, Cushman M, Criqui M, et al. Gender and C-reactive protein: Data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 2006;152:593-8.
18. McConnell JP, Branum EL, Ballman KV, et al. Gender differences in C-reactive protein concentrations - confirmation with two sensitive methods. Clin Chem Lab Med 2002;40:56-9.
19. Pieroni L, Bastard JP, Piton A, et al. Interpretation of circulating C-reactive protein levels in adults: Body mass index and gender are a must. Diabetes Metab 2003;29:133-8.
20. Lloyd-Jones DM, Liu K, Tian L, et al. Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006;145:35-42.
21. Greenland P, O'Malley PG. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 2005;165:2454-6.
22. de Maat MP, de Bart AC, Hennis BC, et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16:1156-62.
23. Chenillot O, Henny J, Steinmetz J, et al. High sensitivity C-reactive protein: Biological variations and reference limits. Clin Chem Lab Med 2000;38:1003-11.
24. Campbell B, Badrick T, Flatman R, et al. Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem 2002;39:85-8.
25. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-8.
26. Nasermoaddeli A, Sekine M, Kagamimori S. Intra-individual variability of high-sensitivity C-reactive protein: Age-related variations over time in Japanese subjects. Circ J 2006;70:559-63.
27. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005;112:666-73.
28. Butler J, Rodondi N, Zhu Y, et al. Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 2006;47:1595-602.
29. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006;21:1-6.
30. McNeill AM, Katz R, Girman CJ, et al. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study. J Am Geriatr Soc 2006;54:1317-24.
31. Tong W, Lai H, Yang C, et al. Age, gender and metabolic syndrome-related coronary heart disease in U.S. adults. Int J Cardiol 2005;104:288-91.
32. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.